BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 36326416)

  • 21. Serum sPD-1 and sPD-L1 as Biomarkers for Evaluating the Efficacy of Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Patients.
    Li Y; Cui X; Yang YJ; Chen QQ; Zhong L; Zhang T; Cai RL; Miao JY; Yu SC; Zhang F
    Clin Breast Cancer; 2019 Oct; 19(5):326-332.e1. PubMed ID: 31176611
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Soluble Programmed Cell Death Ligand-1 (sPD-L1) Levels in Various Cancer Types and Normal Populations.
    Lee SH; Park HJ; Moon JY; Kim YT; Lee KR; Kwak MJ; Kim YJ
    Clin Lab; 2023 Apr; 69(4):. PubMed ID: 37057933
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical significance of soluble programmed cell death-1 and soluble programmed cell death-ligand 1 in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy.
    Tominaga T; Akiyoshi T; Yamamoto N; Taguchi S; Mori S; Nagasaki T; Fukunaga Y; Ueno M
    PLoS One; 2019; 14(2):e0212978. PubMed ID: 30807610
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Significance of soluble PD-L1 in patients with chronic hepatitis B and hepatitis C].
    Ke RM; Ouyang LJ; Li WF; Peng XM
    Zhonghua Gan Zang Bing Za Zhi; 2023 Feb; 31(2):133-137. PubMed ID: 37137827
    [No Abstract]   [Full Text] [Related]  

  • 25. Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma.
    Cho I; Lee H; Yoon SE; Ryu KJ; Ko YH; Kim WS; Kim SJ
    BMC Cancer; 2020 Feb; 20(1):120. PubMed ID: 32054467
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Soluble PD-L1 Expression in Circulation as a Predictive Marker for Recurrence and Prognosis in Gastric Cancer: Direct Comparison of the Clinical Burden Between Tissue and Serum PD-L1 Expression.
    Shigemori T; Toiyama Y; Okugawa Y; Yamamoto A; Yin C; Narumi A; Ichikawa T; Ide S; Shimura T; Fujikawa H; Yasuda H; Hiro J; Yoshiyama S; Ohi M; Araki T; Kusunoki M
    Ann Surg Oncol; 2019 Mar; 26(3):876-883. PubMed ID: 30565045
    [TBL] [Abstract][Full Text] [Related]  

  • 27. sPD-L1 and sPD-L2 in plasma of patients with lung cancer and their clinical significance.
    Han S; Zhang Y; Yuan J; Wu Y; Zhou Y; Zhou Y; Li X; Zhou S
    Cytokine; 2024 Apr; 176():156532. PubMed ID: 38330638
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increase in soluble PD-1 is associated with prolonged survival in patients with advanced EGFR-mutated non-small cell lung cancer treated with erlotinib.
    Sorensen SF; Demuth C; Weber B; Sorensen BS; Meldgaard P
    Lung Cancer; 2016 Oct; 100():77-84. PubMed ID: 27597284
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Soluble PD-L1 as a diagnostic and prognostic biomarker in resectable gastric cancer patients.
    Chivu-Economescu M; Herlea V; Dima S; Sorop A; Pechianu C; Procop A; Kitahara S; Necula L; Matei L; Dragu D; Neagu AI; Bleotu C; Diaconu CC; Popescu I; Duda DG
    Gastric Cancer; 2023 Nov; 26(6):934-946. PubMed ID: 37668884
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The potential of soluble programmed death-ligand 1 (sPD-L1) as a diagnosis marker for colorectal cancer.
    Shao W; Xu Y; Lin S; Gao J; Gao J; Wang H
    Front Oncol; 2022; 12():988567. PubMed ID: 36052227
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Soluble PD-L1 with PD-1-binding capacity exists in the plasma of patients with non-small cell lung cancer.
    Takeuchi M; Doi T; Obayashi K; Hirai A; Yoneda K; Tanaka F; Iwai Y
    Immunol Lett; 2018 Apr; 196():155-160. PubMed ID: 29366663
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Change of Soluble Programmed Death Ligand 1 (sPD-L1) in Plasma of Small Cell Lung Cancer and Its Clinical Significance.
    Lu F; Dong Y; Li Q; Wang M
    Comput Math Methods Med; 2022; 2022():8375349. PubMed ID: 35126639
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The correlation and prognostic value of serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in patients with hepatocellular carcinoma.
    Chang B; Huang T; Wei H; Shen L; Zhu D; He W; Chen Q; Zhang H; Li Y; Huang R; Li W; Wu P
    Cancer Immunol Immunother; 2019 Mar; 68(3):353-363. PubMed ID: 30506460
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Soluble PD-L1: a potential dynamic predictive biomarker for immunotherapy in patients with proficient mismatch repair colorectal cancer.
    He Y; Zhang X; Zhu M; He W; Hua H; Ye F; Zhou X; Chen N; Li Y; Zhong W; Wu G; Cai H; Jiang W
    J Transl Med; 2023 Jan; 21(1):25. PubMed ID: 36639643
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic value of soluble programmed cell death ligand-1 in patients with non-small-cell lung cancer: a meta-analysis.
    Wang Y; He H
    Immunotherapy; 2022 Aug; 14(12):945-956. PubMed ID: 35822688
    [No Abstract]   [Full Text] [Related]  

  • 36. Diagnostic and prognostic value of serum soluble B7-H3 in nonsmall cell lung cancer.
    Li Y; Xu L; Li J; Wang Q; Ma J
    Anticancer Drugs; 2024 Jun; 35(5):426-432. PubMed ID: 38386015
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasma levels of soluble programmed death ligand 1 (sPD-L1) in WHO II/III nasopharyngeal carcinoma (NPC): A preliminary study.
    Yang J; Hu M; Bai X; Ding X; Xie L; Ma J; Fan B; Yu J
    Medicine (Baltimore); 2019 Sep; 98(39):e17231. PubMed ID: 31574833
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Soluble programmed cell death protein 1 (sPD-1) and the soluble programmed cell death ligands 1 and 2 (sPD-L1 and sPD-L2) in lymphoid malignancies.
    Mortensen JB; Monrad I; Enemark MB; Ludvigsen M; Kamper P; Bjerre M; d'Amore F
    Eur J Haematol; 2021 Jul; 107(1):81-91. PubMed ID: 33721375
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative analysis of the levels of soluble forms of receptor and ligand of the immunity control point PD-1/PD-L1 in the blood serum of patients with typical bone osteosarcoma and chondrosarcoma.
    Kushlinskii NE; Alferov AA; Boulytcheva IV; Timofeev YS; Korotkova EA; Khvan OT; Kuzmin YB; Kuznetsov IN; Bondarev AV; Shchupak MY; Sokolov NY; Efimova MM; Gershtein ES; Sushentsov EA; Aliev MD; Musaev ER
    Klin Lab Diagn; 2020 Dec; 65(11):669-675. PubMed ID: 33301655
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Levels of programmed death-1 and programmed death ligand-1 in the peripheral blood of patients with oral squamous cell carcinoma and its clinical implications].
    Zhang P; Ouyang S; Wang J; Huang Z; Wang J; Liao L
    Hua Xi Kou Qiang Yi Xue Za Zhi; 2015 Oct; 33(5):529-33. PubMed ID: 26688950
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.